Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-78c5997874-mlc7c Total loading time: 0 Render date: 2024-11-08T00:38:02.807Z Has data issue: false hasContentIssue false

Chapter 16 - Drug- and therapy-induced lung injury

Published online by Cambridge University Press:  05 June 2014

By
Mary Beth Beasley  and
Glenn A. Rudner
Edited by
Philip Hasleton  and
Douglas B. Flieder
Philip Hasleton
Affiliation:
University of Manchester
Douglas B. Flieder
Affiliation:
Fox Chase Cancer Center, Philadelphia
Get access

Summary

Introduction

Drug-induced lung disease represents one of the more challenging areas of pulmonary medicine from both a clinical and pathological standpoint. Over 300 agents are associated with adverse pulmonary reactions and the list is continually expanding.

Clinically, drug-induced pulmonary disease may manifest as an acute, subacute or chronic reaction. An acute reaction occurs within minutes or hours following exposure. Anaphylaxis, bronchospasm and pulmonary edema are examples of such acute reactions. Subacute reactions occur days to weeks following administration and chronic reactions manifest months to years after initiation of a particular drug. Complicating the picture are drug reactions presenting as an acute lung disease in patients who have taken a drug for years. Additionally, drug reactions may occur after discontinuation of a drug, most notably exemplified by bischloroethyl nitrosourea (BCNU) therapy, in which the drug has been implicated in pulmonary disease years after discontinuation.

Clinical diagnoses of drug toxicity require a high index of suspicion, given that presenting symptoms are not specific and overlap with numerous other pulmonary diseases. Further confounding the picture, a patient may have multiple factors which could potentially contribute to the development of pulmonary disease (e.g. a patient with rheumatoid arthritis on methotrexate or an immunosuppressed patient on chemotherapy). Radiographic findings similarly tend to reflect the wide range of histological findings associated with drug toxicity and are typically not specific by themselves.

Type
Chapter
Information
Spencer's Pathology of the Lung , pp. 585 - 604
Publisher: Cambridge University Press
Print publication year: 2000

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Camus, P, Rosenow, EC. Iatrogenic lung disease. Clin Chest Med 2004;25:XIII–XXIX.CrossRefGoogle ScholarPubMed
Camus, P, Bonniaud, P, Fanton, A, et al. Drug-induced and iatrogenic infiltrative lung disease. Clin Chest Med 2004;25:479–519, vi.CrossRefGoogle ScholarPubMed
O'Driscoll, BR, Hasleton, PS, Taylor, PM, et al. Active lung fibrosis up to 17 years after chemotherapy with carmustine (BCNU) in childhood. N Engl J Med 1990;323:378–82.CrossRefGoogle Scholar
Kobayashi, J, Kitamura, S.KL-6: a serum marker for interstitial pneumonia. Chest 1995;108:311–5.CrossRefGoogle ScholarPubMed
Ohnishi, H, Yokoyama, A, Yasuhara, Y, et al. Circulating KL-6 levels in patients with drug induced pneumonitis. Thorax 2003;58:872–5.CrossRefGoogle ScholarPubMed
Irey, NS.Teaching monograph. Tissue reactions to drugs. Am J Pathol 1976;82:613–47.Google ScholarPubMed
Limper, AH, Rosenow, EC. Drug-induced interstitial lung disease. Curr Opin Pulm Med 1996;2:396–404.CrossRefGoogle ScholarPubMed
Akoun, GM, Cadranel, JL, Rosenow, EC, Milleron, BJ.Bronchoalveolar lavage cell data in drug-induced pneumonitis. Allerg Immunol (Paris) 1991;23:245–52.Google ScholarPubMed
Akoun, GM, Cadranel, JL, Milleron, BJ, D'Ortho, MP, Mayaud, CM.Bronchoalveolar lavage cell data in 19 patients with drug-associated pneumonitis (except amiodarone). Chest 1991;99:98–104.CrossRefGoogle Scholar
Delaunois, LM.Mechanisms in pulmonary toxicology. Clin Chest Med 2004;25(1):1–14.CrossRefGoogle ScholarPubMed
Vahid, B, Marik, PE.Pulmonary complications of novel antineoplastic agents for solid tumors. Chest 2008;133:528–38.CrossRefGoogle ScholarPubMed
Camus, C. Drug Induced Pulmonary Disease. 2011. .
Lee-Chiong, T, Matthay, RA.Drug-induced pulmonary edema and acute respiratory distress syndrome. Clin Chest Med 2004;25:95–104.CrossRefGoogle ScholarPubMed
Gal, AA.Drug and radiation toxicity. In Tomashefski, JR, Cagle, PT, Farver, CF, Fraire, AE, eds. Dail and Hammar's Pulmonary Pathology, 3rd ed. New York: Springer, 2008. pp. 807–30.CrossRefGoogle Scholar
Limper, AH.Chemotherapy-induced lung disease. Clin Chest Med 2004;25:53–64.CrossRefGoogle ScholarPubMed
Tomashefski, JF. Pulmonary pathology of acute respiratory distress syndrome. Clin Chest Med 2000;21:435–66.CrossRefGoogle ScholarPubMed
Travis, W, et al. American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. Am J Respir Crit Care Med 2002;15;165:277–304.Google Scholar
Travis, WD, Colby, TV, Koss, MN, et al. Drug and radiation reactions. Non-neoplastic Disorders of the Lower Respiratory Tract. Washington DC: AFIP Press, 2001.Google Scholar
Travis, WD, Matsui, K, Moss, J, Ferrans, VJ.Idiopathic nonspecific interstitial pneumonia: prognostic significance of cellular and fibrosing patterns: survival comparison with usual interstitial pneumonia and desquamative interstitial pneumonia. Am J Surg Pathol 2000;24:19–33.CrossRefGoogle ScholarPubMed
Travis, WD, Hunninghake, G, King, TE, et al. Idiopathic non-specific interstitial pneumonia. Report of an American Thoracic Society project. Am J Respir Crit Care Med 2008;177:1338–47.CrossRefGoogle Scholar
Epler, GR.Drug-induced bronchiolitis obliterans organizing pneumonia. Clin Chest Med 2004;25:89–94.CrossRefGoogle ScholarPubMed
Cohen, MB, Austin, JH, Smith-Vaniz, A, Lutzky, J, Grimes, MM.Nodular bleomycin toxicity. Am J Clin Pathol 1989;92:101–4.CrossRefGoogle ScholarPubMed
McCrea, ES, Diaconis, JN, Wade, JC, Johnston, CA.Bleomycin toxicity simulating metastatic nodules to the lungs. Cancer 1981;48:1096–100.3.0.CO;2-Y>CrossRefGoogle ScholarPubMed
Santrach, PJ, Askin, FB, Wells, RJ, Azizkhan, RG, Merten, DF.Nodular form of bleomycin-related pulmonary injury in patients with osteogenic sarcoma. Cancer 1989;15;64:806–11.3.0.CO;2-X>CrossRefGoogle Scholar
Epler, GR, Colby, TV, McLoud, TC, Carrington, CB, Gaensler, EA.Bronchiolitis obliterans organizing pneumonia. N Engl J Med 1985;312(3):152–8.CrossRefGoogle ScholarPubMed
Allen, JN.Drug-induced eosinophilic lung disease. Clin Chest Med 2004;25:77–88.CrossRefGoogle ScholarPubMed
Carrington, CB, Addington, WW, Goff, AM, et al. Chronic eosinophilic pneumonia. N Engl J Med 1969;280:787–98.CrossRefGoogle ScholarPubMed
Carrington, CB.Eosinophilic reactions in the lung. N Engl J Med 1969;281:51.Google ScholarPubMed
Pope-Harman, AL, Davis, WB, Allen, ED, Christoforidis, AJ, Allen, JN.Acute eosinophilic pneumonia. A summary of 15 cases and review of the literature. Medicine (Baltimore) 1996;75(6):334–42.CrossRefGoogle ScholarPubMed
Tazelaar, HD, Linz, LJ, Colby, TV, Myers, JL, Limper, AH.Acute eosinophilic pneumonia: histopathologic findings in nine patients. Am J Respir Crit Care Med 1997;155(1):296–302.CrossRefGoogle ScholarPubMed
Wardwell, NR, Miller, R, Ware, LB.Pulmonary alveolar proteinosis associated with a disease-modifying antirheumatoid arthritis drug. Respirology 2006;11(5):663–5.CrossRefGoogle ScholarPubMed
Bedrossian, CW, Luna, MA, Conklin, RH, Miller, WC.Alveolar proteinosis as a consequence of immunosuppression. A hypothesis based on clinical and pathologic observations. Hum Pathol 1980;11(5 Suppl):527–35.Google ScholarPubMed
Schwarz, MI, Fontenot, AP.Drug-induced diffuse alveolar hemorrhage syndromes and vasculitis. Clin Chest Med 2004;25(1):133–40.CrossRefGoogle ScholarPubMed
Nathani, N, Little, MA, Kunst, H, Wilson, D, Thickett, DR.Churg-Strauss syndrome and leukotriene antagonist use: a respiratory perspective. Thorax 2008;63(10):883–8.CrossRefGoogle ScholarPubMed
Gurtner, HP.Pulmonary hypertension, “plexogenic pulmonary arteriopathy” and the appetite depressant drug aminorex: post or propter?Bull Eur Physiopathol Respir 1979;15(5):897–923.Google ScholarPubMed
Higenbottam, T, Laude, L, Emery, C, Essener, M.Pulmonary hypertension as a result of drug therapy. Clin Chest Med 2004;25(1):123–31.CrossRefGoogle ScholarPubMed
Kramer, MS, Lane, DA.Aminorex, dexfenfluramine, and primary pulmonary hypertension. J Clin Epidemiol 1998;51(4):361–4.CrossRefGoogle ScholarPubMed
Mark, EJ, Patalas, ED, Chang, HT, Evans, RJ, Kessler, SC.Fatal pulmonary hypertension associated with short-term use of fenfluramine and phentermine. N Engl J Med 1997;337(9):602–6.CrossRefGoogle ScholarPubMed
Rich, S, Rubin, L, Walker, AM, Schneeweiss, S, Abenhaim, L.Anorexigens and pulmonary hypertension in the United States: results from the surveillance of North American pulmonary hypertension. Chest 2000;117(3):870–4.CrossRefGoogle ScholarPubMed
Ellis, DA, Capewell, SJ.Pulmonary veno-occlusive disease after chemotherapy. Thorax 1986;41(5):415–6.CrossRefGoogle ScholarPubMed
Joselson, R, Warnock, M.Pulmonary veno-occlusive disease after chemotherapy. Hum Pathol 1983;14(1):88–91.CrossRefGoogle ScholarPubMed
Knight, BK, Rose, AG.Pulmonary veno-occlusive disease after chemotherapy. Thorax 1985;40(11):874–5.CrossRefGoogle ScholarPubMed
Lombard, CM, Churg, A, Winokur, S.Pulmonary veno-occlusive disease following therapy for malignant neoplasms. Chest 1987;92(5):871–6.CrossRefGoogle ScholarPubMed
Montani, D, Achouh, L, Dorfmuller, P et al. Pulmonary veno-occlusive disease: clinical, functional, radiologic, and hemodynamic characteristics and outcome of 24 cases confirmed by histology. Medicine (Baltimore) 2008;87(4):220–33.CrossRefGoogle Scholar
Rose, AG.Pulmonary veno-occlusive disease due to bleomycin therapy for lymphoma. Case reports. S Afr Med J 1983;64(16):636–8.Google ScholarPubMed
Doll, DC, Yarbro, JW.Vascular toxicity associated with antineoplastic agents. Semin Oncol 1992;19(5):580–96.Google ScholarPubMed
Butnor, KJ.Pulmonary sarcoidosis induced by interferon-alpha therapy. Am J Surg Pathol 2005;29(7):976–9.CrossRefGoogle ScholarPubMed
Goldberg, HJ, Fiedler, D, Webb, A, et al. Sarcoidosis after treatment with interferon-alpha: a case series and review of the literature. Respir Med 2006;100(11):2063–8.CrossRefGoogle ScholarPubMed
Rosen, Y.Interferon-alpha and sarcoidosis. Am J Surg Pathol 2005;29(11):1544.CrossRefGoogle ScholarPubMed
Chhajed, PN, Dickenmann, M, Bubendorf, L, et al. Patterns of pulmonary complications associated with sirolimus. Respiration 2006;73(3):367–74.CrossRefGoogle ScholarPubMed
Pham, PT, Pham, PC, Danovitch, GM, et al. Sirolimus-associated pulmonary toxicity. Transplantation 2004;77(8):1215–20.CrossRefGoogle ScholarPubMed
Weiner, SM, Sellin, L, Vonend, O, et al. Pneumonitis associated with sirolimus: clinical characteristics, risk factors and outcome – a single-centre experience and review of the literature. Nephrol Dial Transplant 2007;22(12):3631–7.CrossRefGoogle ScholarPubMed
Huggins, JT, Sahn, SA.Drug-induced pleural disease. Clin Chest Med 2004;25(1):141–53.CrossRefGoogle ScholarPubMed
Rosenow, EC, Myers, JL, Swensen, SJ, Pisani, RJ.Drug-induced pulmonary disease. An update. Chest 1992;102(1):239–50.CrossRefGoogle ScholarPubMed
Flieder, DB, Travis, WD.Pathologic characteristics of drug-induced lung disease. Clin Chest Med 2004;25(1):37–45.CrossRefGoogle ScholarPubMed
Morelock, SY, Sahn, SA.Drugs and the pleura. Chest 1999;116(1):212–21.CrossRefGoogle ScholarPubMed
Camus, P, Martin, WJ, Rosenow, EC. Amiodarone pulmonary toxicity. Clin Chest Med 2004;25(1):65–75.CrossRefGoogle ScholarPubMed
Dean, PJ, Groshart, KD, Porterfield, JG, Iansmith, DH, Golden, EB. Amiodarone-associated pulmonary toxicity. A clinical and pathologic study of eleven cases. Am J Clin Pathol 1987;87(1):7–13.CrossRefGoogle ScholarPubMed
Kennedy, JI, Myers, JL, Plumb, VJ, Fulmer, JD.Amiodarone pulmonary toxicity. Clinical, radiologic, and pathologic correlations. Arch Intern Med 1987;147(1):50–5.CrossRefGoogle ScholarPubMed
Myers, JL, Kennedy, JI, Plumb, VJ.Amiodarone lung: pathologic findings in clinically toxic patients. Hum Pathol 1987;18(4):349–54.CrossRefGoogle ScholarPubMed
Bedrossian, CW, Warren, CJ, Ohar, J, Bhan, R.Amiodarone pulmonary toxicity: cytopathology, ultrastructure, and immunocytochemistry. Ann Diagn Pathol 1997;1(1):47–56.CrossRefGoogle ScholarPubMed
Ruangchira-Urai, R, Colby, TV, Klein, J, et al. Nodular amiodarone lung disease. Am J Surg Pathol 2008;32(11):1654–60.CrossRefGoogle ScholarPubMed
Bedrossian, CW, Miller, WC, Luna, MA.Methotrexate-induced diffuse interstitial pulmonary fibrosis. South Med J 1979;72(3):313–8.CrossRefGoogle ScholarPubMed
Imokawa, S, Colby, TV, Leslie, KO, Helmers, RA.Methotrexate pneumonitis: review of the literature and histopathological findings in nine patients. Eur Respir J 2000;15(2):373–81.CrossRefGoogle ScholarPubMed
Kaplan, RL, Waite, DH.Progressive interstitial lung disease from prolonged methotrexate therapy. Arch Dermatol 1978;114(12):1800–2.CrossRefGoogle ScholarPubMed
Kremer, JM, Alarcon, GS, Weinblatt, ME et al. Clinical, laboratory, radiographic, and histopathologic features of methotrexate-associated lung injury in patients with rheumatoid arthritis: a multicenter study with literature review. Arthritis Rheum 1997;40(10):1829–37.CrossRefGoogle ScholarPubMed
Sostman, HD, Matthay, RA, Putman, CE, Smith, GJ.Methotrexate-induced pneumonitis. Medicine (Baltimore) 1976;55(5):371–88.CrossRefGoogle ScholarPubMed
Sostman, HD, Matthay, RA, Putman, CE.Cytotoxic drug-induced lung disease. Am J Med 1977;62(4):608–15.CrossRefGoogle ScholarPubMed
Sostman, HD, Putman, CE, Gamsu, G.Review: diagnosis of chemotherapy lung. AJR Am J Roentgenol 1981;136(1):33–40.CrossRefGoogle ScholarPubMed
Ben Arush, MW, Roguin, A, Zamir, E, et al. Bleomycin and cyclophosphamide toxicity simulating metastatic nodules to the lungs in childhood cancer. Pediatr Hematol Oncol 1997;14(4):381–6.CrossRefGoogle ScholarPubMed
Glasier, CM, Siegel, MJ.Multiple pulmonary nodules: unusual manifestation of bleomycin toxicity. AJR Am J Roentgenol 1981;137(1):155–6.CrossRefGoogle ScholarPubMed
Holoye, PY, Luna, MA, MacKay, B, Bedrossian, CW.Bleomycin hypersensitivity pneumonitis. Ann Intern Med 1978;88(1):47–9.CrossRefGoogle ScholarPubMed
Zucker, PK, Khouri, NF, Rosenshein, NB.Bleomycin-induced pulmonary nodules: a variant of bleomycin pulmonary toxicity. Gynecol Oncol 1987;28(3):284–91.CrossRefGoogle ScholarPubMed
Holmberg, L, Boman, G.Pulmonary reactions to nitrofurantoin. 447 cases reported to the Swedish Adverse Drug Reaction Committee 1966–1976. Eur J Respir Dis 1981;62(3):180–9.Google ScholarPubMed
Sovijarvi, AR, Lemola, M, Stenius, B, Idanpaan-Heikkila, J.Nitrofurantoin-induced acute, subacute and chronic pulmonary reactions. Scand J Respir Dis 1977;58(1):41–50.Google ScholarPubMed
Geller, M, Dickie, HA, Kass, DA, Hafez, GR, Gillespie, JJ.The histopathology of acute nitrofurantoin-associated penumonitis. Ann Allergy 1976;37(4):275–9.Google ScholarPubMed
Hargett, CW, Sporn, TA, Roggli, VL, Hollingsworth, JW.Giant cell interstitial pneumonia associated with nitrofurantoin. Lung 2006;184(3):147–9.CrossRefGoogle ScholarPubMed
Duran, I, Siu, LL, Oza, AM, et al. Characterisation of the lung toxicity of the cell cycle inhibitor temsirolimus. Eur J Cancer 2006;42(12):1875–80.CrossRefGoogle ScholarPubMed
Herbst, RS, Sandler, AB.Non-small cell lung cancer and antiangiogenic therapy: what can be expected of bevacizumab?Oncologist 2004;9(Suppl 1):19–26.CrossRefGoogle ScholarPubMed
Johnson, DH, Fehrenbacher, L, Novotny, WF, et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2004;22(11):2184–91.CrossRefGoogle ScholarPubMed
Sandler, A, Gray, R, Perry, MC et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355(24):2542–50.CrossRefGoogle ScholarPubMed
Vahid, B, Mehrotra, A.Trastuzumab (Herceptin)-associated lung injury. Respirology 2006;11(5):655–8.CrossRefGoogle ScholarPubMed
Radzikowska, E, Szczepulska, E, Chabowski, M, Bestry, I.Organising pneumonia caused by transtuzumab (Herceptin) therapy for breast cancer. Eur Respir J 2003;21(3):552–5.CrossRefGoogle ScholarPubMed
Wagner, SA, Mehta, AC, Laber, DA.Rituximab-induced interstitial lung disease. Am J Hematol 2007;82(10):916–9.CrossRefGoogle ScholarPubMed
Villeneuve, E, St-Pierre, A, Haraoui, B.Interstitial pneumonitis associated with infliximab therapy. J Rheumatol 2006;33(6):1189–93.Google ScholarPubMed
Wiener, CM, Muse, VV, Mark, EJ.Case records of the Massachusetts General Hospital. Case 33–2008. A 63-year-old woman with dyspnea on exertion. N Engl J Med 2008;359(17):1823–32.CrossRefGoogle ScholarPubMed
Leard, LE, Cho, BK, Jones, KD, et al. Fatal diffuse alveolar damage in two lung transplant patients treated with cetuximab. J Heart Lung Transplant 2007;26(12):1340–4.CrossRefGoogle ScholarPubMed
Vahid, B, Esmaili, A.Erlotinib-associated acute pneumonitis: report of two cases. Can Respir J 2007;14(3):167–70.CrossRefGoogle ScholarPubMed
Sumpter, K, Harper-Wynne, C, O'Brien, M, Congleton, J.Severe acute interstitial pneumonia and gefitinib. Lung Cancer 2004;43(3):367–8.CrossRefGoogle ScholarPubMed
Ieki, R, Saitoh, E, Shibuya, M.Acute lung injury as a possible adverse drug reaction related to gefitinib. Eur Respir J 2003;22(1):179–81.CrossRefGoogle ScholarPubMed
Isshiki, I, Yamaguchi, K, Okamoto, S.Interstitial pneumonitis during imatinib therapy. Br J Haematol 2004;125(4):420.CrossRefGoogle ScholarPubMed
Krug, LM, Crapanzano, JP, Azzoli, CG, et al. Imatinib mesylate lacks activity in small cell lung carcinoma expressing c-kit protein: a phase II clinical trial. Cancer 2005;103(10):2128–31.CrossRefGoogle ScholarPubMed
Ma, CX, Hobday, TJ, Jett, JR.Imatinib mesylate-induced interstitial pneumonitis. Mayo Clin Proc 2003;78(12):1578–9.CrossRefGoogle ScholarPubMed
Ohnishi, K, Sakai, F, Kudoh, S, Ohno, R.Twenty-seven cases of drug-induced interstitial lung disease associated with imatinib mesylate. Leukemia 2006;20(6):1162–4.CrossRefGoogle ScholarPubMed
Abratt, RP, Morgan, GW, Silvestri, G, Willcox, P.Pulmonary complications of radiation therapy. Clin Chest Med 2004;25(1):167–77.CrossRefGoogle ScholarPubMed
Abratt, RP, Morgan, GW.Lung toxicity following chest irradiation in patients with lung cancer. Lung Cancer 2002;35(2):103–9.CrossRefGoogle ScholarPubMed
Rosiello, RA, Merrill, WW.Radiation-induced lung injury. Clin Chest Med 1990;11(1):65–71.Google ScholarPubMed
Abid, SH, Malhotra, V, Perry, MC.Radiation-induced and chemotherapy-induced pulmonary injury. Curr Opin Oncol 2001;13(4):242–8.CrossRefGoogle ScholarPubMed
Abratt, RP, Morgan, GW, Silvestri, G, Willcox, P.Pulmonary complications of radiation therapy. Clin Chest Med 2004;25(1):167–77.CrossRefGoogle ScholarPubMed
Movsas, B, Raffin, TA, Epstein, AH, Link, CJ. Pulmonary radiation injury. Chest 1997;111(4):1061–76.CrossRefGoogle ScholarPubMed
Thomas, PS, Agrawal, S, Gore, M, Geddes, DM.Recall lung pneumonitis due to carmustine after radiotherapy. Thorax 1995;50(10):1116–8.CrossRefGoogle ScholarPubMed
Greene, FL, Page, DL, Fleming, D, et al. Lung. AJCC Cancer Staging Manual. 6th ed. New York: Springer, 2002. pp. 165–77.CrossRefGoogle Scholar
Junker, K, Langner, K, Klinke, F, Bosse, U, Thomas, M.Grading of tumor regression in non-small cell lung cancer: morphology and prognosis. Chest 2001;120(5):1584–91.CrossRefGoogle ScholarPubMed
Junker, K, Thomas, M, Schulmann, K, et al. Tumour regression in non-small-cell lung cancer following neoadjuvant therapy. Histological assessment. J Cancer Res Clin Oncol 1997;123(9):469–77.CrossRefGoogle ScholarPubMed
Liu-Jarin, X, Stoopler, MB, Raftopoulos, H, et al. Histologic assessment of non-small cell lung carcinoma after neoadjuvant therapy. Mod Pathol 2003;16(11):1102–8.CrossRefGoogle ScholarPubMed
Clasen, S, Krober, SM, Kosan, B, et al. Pathomorphologic evaluation of pulmonary radiofrequency ablation: proof of cell death is characterized by DNA fragmentation and apoptotic bodies. Cancer 2008;113(11):3121–9.CrossRefGoogle ScholarPubMed
Danielson, C, Benjamin, RJ, Mangano, MM, Mills, CJ, Waxman, DA.Pulmonary pathology of rapidly fatal transfusion-related acute lung injury reveals minimal evidence of diffuse alveolar damage or alveolar granulocyte infiltration. Transfusion 2008;48(11):2401–8.CrossRefGoogle ScholarPubMed
Kopko, PM, Popovsky, MA.Pulmonary injury from transfusion-related acute lung injury. Clin Chest Med 2004;25(1):105–11.CrossRefGoogle ScholarPubMed
Toy, P, Popovsky, MA, Abraham, E, et al. Transfusion-related acute lung injury: definition and review. Crit Care Med 2005;33(4):721–6.CrossRefGoogle ScholarPubMed
Bell, MD.Pathology of drug abuse-lung disease. In Karch, SB, ed. Drug Abuse Handbook. Boca Raton: CRC Press, 1998. pp. 129–35.Google Scholar
Stephens, BG.Investigation of deaths from drug abuse. In Spitz, WU, ed. Spitz and Fisher's Medicolegal Investigation of Death. Guidelines for the Application of Pathology to Crime Investigation. 3rd ed. Springfield: Charles C. Thomas, 1993. pp. 733–66.Google Scholar
Murray, RJ, Smialek, JE, Golle, M, Albin, RJ.Pulmonary artery medial hypertrophy in cocaine users without foreign particle microembolization. Chest 1989;96(5):1050–3.CrossRefGoogle ScholarPubMed
Murray, RJ, Albin, RJ, Mergner, W, Criner, GJ.Diffuse alveolar hemorrhage temporally related to cocaine smoking. Chest 1988;93(2):427–9.CrossRefGoogle ScholarPubMed
Bailey, ME, Fraire, AE, Greenberg, SD, Barnard, J, Cagle, PT.Pulmonary histopathology in cocaine abusers. Hum Pathol 1994;25(2):203–7.CrossRefGoogle ScholarPubMed
Cucco, RA, Yoo, OH, Cregler, L, Chang, JC.Nonfatal pulmonary edema after “freebase” cocaine smoking. Am Rev Respir Dis 1987;136(1):179–81.CrossRefGoogle ScholarPubMed
Tomashefski, JF, Felo, J.The pulmonary pathology of drug and illicit substance abuse. Current Diagnostic Pathology 2004;10(5):413–26.CrossRefGoogle Scholar
Tashkin, DP, Coulson, AH, Clark, VA, et al. Respiratory symptoms and lung function in habitual heavy smokers of marijuana alone, smokers of marijuana and tobacco, smokers of tobacco alone, and nonsmokers. Am Rev Respir Dis 1987;135(1):209–16.Google ScholarPubMed
Johnson, MK, Smith, RP, Morrison, D, Laszlo, G, White, RJ.Large lung bullae in marijuana smokers. Thorax 2000;55(4):340–2.CrossRefGoogle ScholarPubMed
Roth, MD, Arora, A, Barsky, SH, et al. Airway inflammation in young marijuana and tobacco smokers. Am J Respir Crit Care Med 1998;157(3 Pt 1):928–37.CrossRefGoogle ScholarPubMed
Gill, A.Bong lung: regular smokers of cannabis show relatively distinctive histologic changes that predispose to pneumothorax. Am J Surg Pathol 2005;29(7):980–2.CrossRefGoogle ScholarPubMed
Baldwin, GC, Tashkin, DP, Buckley, DM, et al. Marijuana and cocaine impair alveolar macrophage function and cytokine production. Am J Respir Crit Care Med 1997;156(5):1606–13.CrossRefGoogle ScholarPubMed
Hamadeh, R, Ardehali, A, Locksley, RM, York, MK.Fatal aspergillosis associated with smoking contaminated marijuana, in a marrow transplant recipient. Chest 1988;94(2):432–3.CrossRefGoogle Scholar
Dinis-Oliveira, RJ, Duarte, JA, Sanchez-Navarro, A, et al. Paraquat poisonings: mechanisms of lung toxicity, clinical features, and treatment. Crit Rev Toxicol 2008;38:13–71.CrossRefGoogle ScholarPubMed
Higenbottam, T, Crome, P, Parkinson, C, Nunn, J.Further clinical observations on the pulmonary effects of paraquat ingestion. Thorax 1979;34(2):161–5.CrossRefGoogle ScholarPubMed
Rebello, G, Mason, JK.Pulmonary histological appearances in fatal paraquat poisoning. Histopathology 1978;2(1):53–66.CrossRefGoogle ScholarPubMed
Dearden, LC, Fairshter, RD, McRae, DM, et al. Pulmonary ultrastructure of the late aspects of human paraquat poisoning. Am J Pathol 1978;93(3):667–80.Google ScholarPubMed
Levin, PJ, Klaff, LJ, Rose, AG, Ferguson, AD.Pulmonary effects of contact exposure to paraquat: a clinical and experimental study. Thorax 1979;34(2):150–60.CrossRefGoogle ScholarPubMed
Fischman, MW, Schuster, CR, Resnekov, L, et al. Cardiovascular and subjective effects of intravenous cocaine administration in humans. Arch Gen Psychiatry 1976;33(8):983–9.CrossRefGoogle ScholarPubMed
Ganesan, S, Felo, J, Saldana, M, et al. Embolized crospovidone (poly[N-vinyl-2-pyrrolidone]) in the lungs of intravenous drug users. Mod Pathol 2003;16(4):286–92.CrossRefGoogle ScholarPubMed
Tomashefski, JF, Hirsch, CS.The pulmonary vascular lesions of intravenous drug abuse. Hum Pathol 1980;11(2):133–45.CrossRefGoogle ScholarPubMed
Waller, BF, Brownlee, WJ, Roberts, WC.Self-induced pulmonary granulomatosis. A consequence of intravenous injection of drugs intended for oral use. Chest 1980;78(1):90–4.CrossRefGoogle ScholarPubMed
Arnett, EN, Battle, WE, Russo, JV, Roberts, WC.Intravenous injection of talc-containing drugs intended for oral use. A cause of pulmonary granulomatosis and pulmonary hypertension. Am J Med 1976;60(5):711–8.CrossRefGoogle ScholarPubMed
Zeltner, TB, Nussbaumer, U, Rudin, O, Zimmermann, A.Unusual pulmonary vascular lesions after intravenous injections of microcrystalline cellulose. A complication of pentazocine tablet abuse. Virchows Arch A Pathol Anat Histol 1982;395(2):207–16.CrossRefGoogle ScholarPubMed
Crouch, E, Churg, A.Progressive massive fibrosis of the lung secondary to intravenous injection of talc. A pathologic and mineralogic analysis. Am J Clin Pathol 1983;80(4):520–6.CrossRefGoogle ScholarPubMed
Wolff, AJ, O'Donnell, AE.Pulmonary effects of illicit drug use. Clin Chest Med 2004;25(1):203–16.CrossRefGoogle ScholarPubMed
Kringsholm, B, Christoffersen, P.The nature and occurrence of birefingement material in different organs in fatal drug addiction. For Sci Inter 1987; 34(1):53–62.Google ScholarPubMed

Save book to Kindle

To save this book to your Kindle, first ensure [email protected] is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×